Clinical Implications of Opioid Therapy.
Journal
Cancer treatment and research
ISSN: 0927-3042
Titre abrégé: Cancer Treat Res
Pays: United States
ID NLM: 8008541
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
26
11
2021
Statut:
ppublish
Résumé
Although opioids are potent central acting broad-spectrum analgesics, their effectiveness is diminished by various factors pertaining to their metabolism, drug interactions, genetic issues, adverse/side effects, and potential for abuse. All these factors present potential barriers to effective analgesia requiring specific considerations in clinical practice, which include monitoring and case-based intervention.
Identifiants
pubmed: 34542879
doi: 10.1007/978-3-030-81526-4_8
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-124Informations de copyright
© 2021. Springer Nature Switzerland AG.
Références
Swegle JM, Logemann C (2006) Management of common opioid-induced adverse effects. Am Fam Phys 74(8):1347–1354
Meuser T et al (2001) Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93(3):247–257
doi: 10.1016/S0304-3959(01)00324-4
Silverman SM (2009) Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Phys 12(3):679–684
doi: 10.36076/ppj.2009/12/679
Hojsted J, Sjogren P (2007) Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 11(5):490–518
doi: 10.1016/j.ejpain.2006.08.004
Ives TJ et al (2006) Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 6:46
doi: 10.1186/1472-6963-6-46
Chou R et al (2009) Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American pain society and american academy of pain medicine clinical practice guideline. J Pain 10(2):131-146.e5
doi: 10.1016/j.jpain.2008.10.009
Dixon DW (2020) Opioid abuse clinical presentation: history, physical, causes, medscape, 26 Mar. 2020, emedicine.medscape.com/article/287790-clinical
Hahn KL (2011) Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs. Am Health Drug Benefits. 4(2):107–114
pubmed: 25126342
pmcid: 4106581
Hill S (1997) Guidelines for treatment of cancer pain. Cancer pain: opioid tolerance and dependence. www.texascancer.info/gftocp/opioid_tolerance.html
Schuster M, Bayer O, Heid F, Laufenberg-Feldmann R (2018) Opioid rotation in cancer pain treatment. Dtsch Arztebl Int 115(9):135–142. https://doi.org/10.3238/arztebl.2018.0135
doi: 10.3238/arztebl.2018.0135
pubmed: 29563006
pmcid: 5876542
Lin CP., Lu DH (2018) Role of neuroinflammation in opioid tolerance: translational evidence from human-to-rodent studies. In: Shyu BC, Tominaga M (eds) Advances in pain research: mechanisms and modulation of chronic pain. Advances in experimental medicine and biology, vol 1099. Springer, Singapore. https://doi.org/10.1007/978-981-13-1756-9_11
Portenoy R (2015) Cancer pain management with opioids: optimizing analgesia. UpToDate. www.uptodate.com/contents/cancer-pain-management-with-opioids-optimizing-analgesia
Dowell D, Haegerich TM, Chou R (2016) CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep 65(1):1–49
doi: 10.15585/mmwr.rr6501e1
Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L (2011) A comprehensive review of opioid-induced hyperalgesia. Pain Phys 14(2):145–161
doi: 10.36076/ppj.2011/14/145
Mao J, Sung B, Ji RR, Lim G (2002) Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 22:8312
doi: 10.1523/JNEUROSCI.22-18-08312.2002
Vanderah TW, Suenaga NM, Ossipov MH et al (2001) Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci 21:279
doi: 10.1523/JNEUROSCI.21-01-00279.2001
Portenoy R (2015) Prevention and management of side effects in patients receiving opioids for chronic pain. UpToDate 2015. https://www.uptodate.com/contents/prevention-and-management-of-side-effects-in-patients-receiving-opioids-for-chronic-pain
Chen L, Sein M, Vo T, Amhmed S, Zhang Y, Hilaire KS, Houghton M, Mao J (2014) Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia. J Opioid Manag 10(6):383–393. https://doi.org/10.5055/jom.2014.0235 . PubMed PMID: 25531956
Sloan TB (2002) Anesthetics and the brain. Anesthesiol Clin North America 20:265–292
doi: 10.1016/S0889-8537(01)00002-5
Galer BS, Lee D, Ma T, Nagle B, Schlagheck TG (2005) MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: Three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain 115:284–295
doi: 10.1016/j.pain.2005.03.004
King MR, Ladha KS, Gelineau AM, Anderson TA (2016) Perioperative dextromethorphan asan adjunct for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology 124(3):696–705. https://doi.org/10.1097/ALN.0000000000000950 PubMed PMID: 26587683
doi: 10.1097/ALN.0000000000000950
pubmed: 26587683
Dalal S, Bruera E (2019) Pain management for patients with advanced cancer in the opioid epidemic era. Am Soc Clin Oncol Educ Book 39:24–35. https://doi.org/10.1200/EDBK_100020
doi: 10.1200/EDBK_100020
pubmed: 31099619
Carmichael AN, Morgan L, Del Fabbro E (2016) Identifying and assessing the risk of opioid abuse in patients with cancer: an integrative review. Subst Abuse Rehabil. 7:71–79. Medline, Google Scholar
McCabe SE, Cranford JA, Boyd CJ, Teter CJ (2003) Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007; 32:562. Community Epidemiology Work Group. Epidemiologic Trends in Drug Abuse, Vol. II. Proceedings of the Community Epidemiology Work Group, December 2003. NIH Pub No. 04–5365
Center for Drug Evaluation and Research (2018) About FDA Guidances. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs
Scholl L, Seth P, Kariisa M et al (2018) Drug and opioid-involved overdose deaths—United States. 2013–2017. MMWR Morb Mortal Wkly Rep 67:1419–1427
Dowell D, Haegerich TM, Chou R (2016) CDC guideline for prescribing opioids for chronic pain-united states, 2016. JAMA 315(15):1624–1645. https://doi.org/10.1001/jama.2016.1464
doi: 10.1001/jama.2016.1464
pubmed: 26977696
pmcid: 6390846
Childers JW, King LA, Arnold RM (2015) Chronic pain and risk factors for opioid misuse in a palliative care clinic. Am J Hosp Palliat Care 32:654–659
doi: 10.1177/1049909114531445
De la Cruz M, Reddy A, Balankari V et al (2017) The impact of an educational program on patient practices for safe use, storage, and disposal of opioids at a comprehensive cancer center. Oncologist 22:115–121
doi: 10.1634/theoncologist.2016-0266
Iwanicki JL, Severtson SG, McDaniel H et al (2016) Abuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United States. PLoS One 11:e0167499
Bohnert ASB, Valenstein M, Bair MJ et al (2011) Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 305:1315–1321
doi: 10.1001/jama.2011.370
US Department of Health and Human Services, Substance abuse and mental health services administration. Results from the 2007 national survey on drug use and health: national findings. Rockville, MD; 2008. DHHS Publication No. (SMA) 08-4343. http://oas.samhsa.gov/nsduh/2k7nsduh/2k7Results.pdf . Accessed 14 Aug 2008
US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Treatment episode data set (TEDS) 1996–2006. National admissions to substance abuse treatment services. Rockville, MD; 2008. DASIS Series S-43, DHHS Publication No. (SMA) 08-4347
Comer SD, Sullivan MA, Vosburg SK et al (2010) Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 105:709–718
doi: 10.1111/j.1360-0443.2009.02843.x
Acura Pharmaceuticals. Acurox with Niacin tablets. 2010. http://acurapharm.com/products/acurox-tablets/ . Accessed May 11 2010
Laxmaiah Manchikanti M et al (2017) Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American society of interventional pain physician (ASIPP) guidelines. Pain Physician 20(3):S3–S92
doi: 10.36076/ppj.2017.s92
Knezevic NN et al (2017) Repeated quantitative urine toxicology analysis may improve chronic pain patient compliance with opioid therapy. Pain Phys 20(2S):S135–S145
doi: 10.36076/ppj.2017.s145
Manchikanti L et al (2006) Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Phys 9(2):123–129
Shults TF, MS J (2009) Medical review officer handbook. 9th ed
Goldberg DS, Rich BA (2014) Few benefits, likely harms: against universal random urine drug screening in pain management. Pain Med 15(12):2000–2001
doi: 10.1111/pme.12604_3
Owen GT et al (2012) Urine drug testing: current recommendations and best practices. Pain Phys 15(3 Suppl):ES119–ES133
Kaye AD, PhD M et al (2014) Ethical perspectives on urine drug screening for pain physicians. Pain Phys 17(5):E559–E564
Heit HA, Gourlay MDL (2004) Urine drug testing in pain medicine. J Pain and Sympt Manage 27(3):260–267
Younger J et al (2014) The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol 33(4):451–459. https://doi.org/10.1007/s10067-014-2517-2 Epub 2014 Feb 15
doi: 10.1007/s10067-014-2517-2
pubmed: 24526250
pmcid: 3962576
Li Z et al (2018) Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol 61:178–184. https://doi.org/10.1016/j.intimp.2018.05.020 Epub 2018 Jun 7
doi: 10.1016/j.intimp.2018.05.020
pubmed: 29885638
Patten D et al (2018) The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy 38(3):382–389. https://doi.org/10.1002/phar.2086 Epub 2018 Feb 23
doi: 10.1002/phar.2086
pubmed: 29377216
Miskoff J et al (2018) Low dose naltrexone and lung cancer: a case report and discussion. Cureus 10(7):e2924. Published online 2018 Jul 5. https://doi.org/10.7759/cureus.2924
Mathews P et al (1983) Enhancement of natural cytotoxicity by beta-endorphin. J Immunol 130(4):1658–1662
pubmed: 6300232
Sittl R et al Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Therapeut 25(1):150–168
Younger J et al (2009) Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 10(4):663–672. https://doi.org/10.1111/j.1526-4637.2009.00613.x . Epub 2009 Apr 22.
https://www.rxlist.com/belbuca-drug.htm#description . 27 Oct 2019
Pleuvry B, Receptors, agonists and antagonists. Anaesthesia & Intensive Care Medicine. Volume 5, Issue 10, 2004, Pages 350–352, ISSN 1472–0299, https://doi.org/10.1383/anes.5.10.350.52312
Sittl R (2006) Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 20(Suppl 1):s25-30
pubmed: 16764218
Foster B et al (2013) Buprenorphine. J Pain Symptom Manage 45(5):939–949
doi: 10.1016/j.jpainsymman.2013.03.001
Pergolizzi J et al The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Current Med Res Opin 25(6):1517–1528. https://doi.org/10.1185/03007990902920731
Schmidt-Hansen M et al (2016) The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review. BMJ Support Palliat Care 6(3):292–306. https://doi.org/10.1136/bmjspcare-2015-000939 Epub 2015 Dec 15
doi: 10.1136/bmjspcare-2015-000939
pubmed: 26669324
Newmark J (2019) When and how to wean patients off opioids. Practical Pain Management. https://www.practicalpainmanagement.com/resource-centers/opioid-prescribing-monitoring/when-how-wean-patients-opioids . 26 Sept 2019
Oregon Pain Guidance Group. Tapering—guidance & tools. Clinical Update Dec. 2018 https://www.practicalpainmanagement.com/resource-centers/opioid-prescribing-monitoring/when-how-wean-patients-opioids . 26 Sept 2019
Burma NE et al (2017) Therapies and mechanisms of opioid withdrawal. Pain Manag 7(6):455–459. https://doi.org/10.2217/pmt-2017-0028 Epub 2017 Nov 10
doi: 10.2217/pmt-2017-0028
pubmed: 29125396
Rehni AK et al (2013) Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets. CNS Neurol Disord Drug Targets 12(1):112–125
doi: 10.2174/1871527311312010017
Portenoy RK (2000) Contemporary diagnosis and management of pain in oncological and AIDS patients, ed 3. Handbooks in Health Care Company, Newtown, PA